Should You Buy vTv Therapeutics Inc (VTVT) Stock on Wednesday?

vTv Therapeutics Inc (VTVT) stock has risen 48.38% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

vTv Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on VTVT!

See Full VTVT Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With VTVT Stock Today?

vTv Therapeutics Inc (VTVT) stock is up 13.88% while the S&P 500 has fallen -0.06% as of 1:32 PM on Wednesday, Mar 20. VTVT is higher by $2.90 from the previous closing price of $20.90 on volume of 17,724 shares. Over the past year the S&P 500 has risen 30.97% while VTVT has fallen -21.71%. VTVT lost -$9.71 per share in the over the last 12 months. To screen for more stocks like vTv Therapeutics Inc click here.

More About vTv Therapeutics Inc

vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders. Click Here to get the full Stock Report for vTv Therapeutics Inc stock.